期刊
STRUCTURE
卷 23, 期 12, 页码 2319-2330出版社
CELL PRESS
DOI: 10.1016/j.str.2015.10.014
关键词
-
资金
- AbbVie
- Bayer Pharma AG
- Boehringer Ingelheim
- Canada Foundation for Innovation
- Genome Canada
- GlaxoSmithKline
- Janssen
- Lilly Canada
- Merck Co.
- Novartis Research Foundation
- Ontario Ministry of Economic Development and Innovation
- Pfizer
- Sao Paulo Research Foundation-FAPESP
- Takeda
- Wellcome Trust [092809/Z/10/Z]
- E.P. Abraham Cephalosporin Fund
- Linacre College
DNA polymerase theta (Pol theta) has been identified as a crucial alternative non-homologous end-joining factor in mammalian cells. Pol theta is upregulated in a range of cancer cell types defective in homologous recombination, and knockdown has been shown to inhibit cell survival in a subset of these, making it an attractive target for cancer treatment. We present crystal structures of the helicase domain of human Pol theta in the presence and absence of bound nucleotides, and a characterization of its DNA-binding and DNA-stimulated ATPase activities. Comparisons with related helicases from the Hel308 family identify several unique features. Pol theta exists as a tetramer both in the crystals and in solution. We propose a model for DNA binding to the Pol theta helicase domain in the context of the Pol theta tetramer, which suggests a role for the helicase domain in strand annealing of DNA templates for subsequent processing by the polymerase domain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据